Carsten Kobe

7.1k total citations · 1 hit paper
187 papers, 3.0k citations indexed

About

Carsten Kobe is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Carsten Kobe has authored 187 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Pulmonary and Respiratory Medicine, 98 papers in Radiology, Nuclear Medicine and Imaging and 93 papers in Pathology and Forensic Medicine. Recurrent topics in Carsten Kobe's work include Lymphoma Diagnosis and Treatment (91 papers), Lung Cancer Treatments and Mutations (73 papers) and Medical Imaging Techniques and Applications (58 papers). Carsten Kobe is often cited by papers focused on Lymphoma Diagnosis and Treatment (91 papers), Lung Cancer Treatments and Mutations (73 papers) and Medical Imaging Techniques and Applications (58 papers). Carsten Kobe collaborates with scholars based in Germany, Netherlands and United States. Carsten Kobe's co-authors include Markus Dietlein, Alexander Drzezga, Thomas Fischer, Andreas Engert, Peter Borchmann, H Schicha, Felix Dietlein, Bernd Neumaier, Klaus Schomäcker and Boris D. Zlatopolskiy and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Carsten Kobe

173 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

2015 286 citations Markus Dietlein, Carsten Kobe et al. Molecular Imaging and Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carsten Kobe Germany	31	1.6k	1.4k	941	754	352	187	3.0k
Caroline Bodet‐Milin France	28	1.3k 0.8×	529 0.4×	701 0.7×	678 0.9×	218 0.6×	114	2.3k
Alexander Becherer Austria	24	853 0.5×	737 0.5×	515 0.5×	395 0.5×	393 1.1×	65	2.3k
Ebrahim S. Delpassand United States	27	767 0.5×	627 0.4×	372 0.4×	1.1k 1.4×	336 1.0×	77	2.4k
Niklaus Schaefer Switzerland	28	1.3k 0.8×	734 0.5×	502 0.5×	519 0.7×	305 0.9×	117	2.5k
Michael Zimny Germany	28	1.3k 0.8×	674 0.5×	300 0.3×	386 0.5×	116 0.3×	82	2.2k
S. N. Reske Germany	27	1.4k 0.9×	991 0.7×	440 0.5×	630 0.8×	259 0.7×	78	2.8k
Inga Buchmann Germany	20	788 0.5×	376 0.3×	467 0.5×	507 0.7×	525 1.5×	49	1.8k
Stéphane Bardet France	33	1.3k 0.8×	624 0.4×	724 0.8×	478 0.6×	312 0.9×	90	3.3k
Anne Devillers France	23	850 0.5×	378 0.3×	235 0.2×	526 0.7×	319 0.9×	77	1.8k
Flavio Crippa Italy	30	962 0.6×	1.1k 0.8×	609 0.6×	1.1k 1.4×	209 0.6×	124	3.2k

Countries citing papers authored by Carsten Kobe

Since Specialization

Citations

This map shows the geographic impact of Carsten Kobe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten Kobe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten Kobe more than expected).

Fields of papers citing papers by Carsten Kobe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carsten Kobe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten Kobe. The network helps show where Carsten Kobe may publish in the future.

Co-authorship network of co-authors of Carsten Kobe

This figure shows the co-authorship network connecting the top 25 collaborators of Carsten Kobe. A scholar is included among the top collaborators of Carsten Kobe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carsten Kobe. Carsten Kobe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fink, Anna‐Maria, Felix Dietlein, Philipp Krapf, et al.. (2025). Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy. EJNMMI Research. 15(1). 4–4. 1 indexed citations

Schüler, Martin, J. Hense, Kaid Darwiche, et al.. (2024). Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy inEGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance. Journal of Nuclear Medicine. 65(6). 851–855. 3 indexed citations

Rosenbrock, Johannes, Michael Oertel, Eren Celik, et al.. (2024). Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group. International Journal of Radiation Oncology*Biology*Physics. 120(5). 1344–1352. 1 indexed citations

Wegen, Simone, Ursula Nestle, Constantinos Zamboglou, et al.. (2024). Implementation of PET/CT in radiation oncology—a patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation Oncology. Strahlentherapie und Onkologie. 200(11). 931–941. 3 indexed citations

Wegen, Simone, Johannes Rosenbrock, Maike Trommer, et al.. (2024). Impact of FAPI-46/dual-tracer PET/CT imaging on radiotherapeutic management in esophageal cancer. Radiation Oncology. 19(1). 44–44. 7 indexed citations

Voltin, Conrad‐Amadeus, et al.. (2023). PET/CT Reconstruction and Its Impact on [Measures of] Metabolic Tumor Volume. Academic Radiology. 31(7). 3020–3025. 4 indexed citations

Krapf, Philipp, et al.. (2023). Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer. EJNMMI Research. 13(1). 83–83. 9 indexed citations

Wegen, Simone, Christian Baues, Shachi Jenny Sharma, et al.. (2022). Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer. Molecular Imaging and Biology. 24(6). 986–994. 25 indexed citations

Sasse, Stephanie, Annette Plütschow, Andreas Hüttmann, et al.. (2020). AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial. Blood. 136(Supplement 1). 31–32. 8 indexed citations

10.

Baues, Christian, Helen Goergen, Michael Fuchs, et al.. (2019). Consolidating Involved Field Radiotherapy Prevents Early and Local Recurrences in Early Stage Hodgkin Lymphoma. International Journal of Radiation Oncology*Biology*Physics. 105(1). S32–S33. 2 indexed citations

11.

Hellmich, Martin, et al.. (2013). Krankheitsfreies Überleben bei papillärem und follikulärem Schilddrüsenkarzinom. Nuklearmedizin - NuclearMedicine. 52(3). 71–80. 4 indexed citations

12.

Kobe, Carsten, Mathias Schmidt, Deniz Kahraman, et al.. (2012). Calcitonin-Screening bei Patienten mit Schilddrüsenknoten – Diagnostische Bedeutung. Nuklearmedizin - NuclearMedicine. 51(6). 228–233. 4 indexed citations

13.

Eggers, Carsten, Andreas Holstein, Christine Schneider, et al.. (2012). 123I-FP-CIT-SPECT zur Darstellung des Dopaminstatus – Vergleich der visuellen Beurteilung des dopaminergen Degenerationsmusters und der quantitiativen Auswertung mit 2D-manueller und 3D-automatisierter Methode. Nuklearmedizin - NuclearMedicine. 51(6). 244–251. 5 indexed citations

14.

Kahraman, Deniz, Matthias Scheffler, Thomas Zander, et al.. (2011). Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using ¹⁸F-FDG and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET. Journal of Nuclear Medicine. 52(12). 1871–1877. 60 indexed citations

15.

Dietlein, Markus, et al.. (2010). Rekombinantes humanes TSH im Vergleich zur Hypothyreose. Nuklearmedizin - NuclearMedicine. 49(6). 216–224. 12 indexed citations

16.

Dietlein, Markus, Thomas Fischer, Hinrich P. Hansen, et al.. (2010). Entwicklung von Anti-CD30-Radioimmunkonstrukten zur Behandlung des Hodgkin-Lymphoms – Studien an Zellkulturen und Tieren. Nuklearmedizin - NuclearMedicine. 49(3). 97–105. 6 indexed citations

17.

Furth, Christian, Ingo G. Steffen, Holger Amthauer, et al.. (2009). Early and Late Therapy Response Assessment With [ ¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial. Journal of Clinical Oncology. 27(26). 4385–4391. 96 indexed citations

18.

Nogová, Lucia, Ronald Boellaard, Carsten Kobe, et al.. (2009). Downregulation of ¹⁸F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus. Journal of Nuclear Medicine. 50(11). 1815–1819. 24 indexed citations

19.

Dietlein, Markus, et al.. (2008). Adipositas, Stoffwechsel und Schilddrüse Ist der grenzwertig hohe TSH-Spiegel Ursache oder Sekundärphänomen der Adipositas?. Nuklearmedizin - NuclearMedicine. 47(5). 181–187. 9 indexed citations

20.

Kobe, Carsten, W. Eschner, F. Sudbrock, et al.. (2008). Morbus Basedow - Hängt der Erfolg der Radioiodablation von der thyreostatischen Medikation ab?. Nuklearmedizin - NuclearMedicine. 47(4). 153–166. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact